Department of Radiobiology, Faculty of Military Health Sciences, University of Defence in Brno, 500 01 Hradec Kralove, Czech Republic.
Biomedical Research Center, University Hospital, 500 05 Hradec Kralove, Czech Republic.
Curr Drug Targets. 2018;19(16):1943-1957. doi: 10.2174/1389450119666180406110743.
This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
本文综述了近年来人们对 p53 上调凋亡介体(PUMA)在分子途径中作用的认识进展,及其在潜在治疗应用中的作用。特别强调了 PUMA 在电离辐射诱导信号转导中的作用,因为正常组织的放射毒性主要通过细胞凋亡介导。本文描述了 PUMA 及其依赖 p53 和不依赖 p53 的诱导作用,并提出将其作为开发放射保护剂的新靶点的可能性。还讨论了包括将 PUMA 作为靶点以预防和治疗心血管和神经退行性疾病的进一步意义,以及其他治疗应用的概述。最后,还描述了新型 PUMA 调节剂的基本化学结构,如 pifithrine 衍生物、激酶抑制剂或 Bcl-2 蛋白家族调节剂。